 HOUSTON, June 15, 2021 PRNewswire -- Moleculin Biotech, Inc. , Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that as part of the annual reconstitution of the Russell stock indexes, Moleculin has been selected to be added to the Russell 2000 Index effective after the close of the U.S. equity markets on June 25, 2021. We are pleased to have been included in this years reconstitution of the Russell 2000 Index. 